Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

GC Biopharma receives Guatemala approval for BARYCELA antibiotic-free varicella vaccine targeting chickenpox prevention
Vaccine, infectious disease, live attenuated vaccine, varicella, antibiotic-free manufacturing - Read more

Norgine's PEDMARQSI (sodium thiosulfate) wins Swissmedic approval for preventing cisplatin-induced hearing loss in children
Small molecule, cancer, sodium thiosulfate, pediatric oncology, ototoxicity prevention - Read more

Health Canada approves Henlius Biotech's BILDYOS and TUZEMTY (denosumab) biosimilars for osteoporosis and cancer bone complications
Antibody, cancer, monoclonal antibody, osteoporosis, bone metastases, RANKL inhibitor - Read more

Novo Nordisk wins FDA approval for Awiqli (insulin icodec-abae) targeting type 2 diabetes following Ph3 trials
Protein therapy, metabolic, insulin, type 2 diabetes, once-weekly dosing - Read more

FDA approves Rocket Pharmaceuticals' Kresladi (marnetegragene autotemcel) gene therapy for severe leukocyte adhesion deficiency type I
Gene therapy, autoimmune, lentiviral vector, severe leukocyte adhesion deficiency type I, ITGB2 mutations - Read more

Insilico Medicine, Tenacia Biotechnology expand AI-driven CNS collaboration with $94.75M deal value
Research collaboration, neurological, AI/ML, small molecule, milestone payments - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Kodiak Sciences reports positive Ph3 results for Zenkuda (tarcocimab tedromer) anti-VEGF therapy in diabetic retinopathy
Antibody, ophthalmology, anti-VEGF, diabetic retinopathy, intravitreal injection - Read more

Neion Bio emerges from stealth with egg-based biosimilar partnership to develop three monoclonal antibodies
Monoclonal antibody, biosimilar, strategic, operational, cost reduction - Read more

Pinnacle Medicines raises $89M Series B, advancing oral peptide therapeutics platform
Oral peptide drugs, immunology, cardiometabolic, AI-driven platform, clinical-stage - Read more

Vaxess rebrands to Terrestrial Bio, raises $50M to pivot patch technology from vaccines to GLP-1 obesity drug delivery
Transdermal delivery, GLP-1 receptor agonists, patch technology, obesity, platform technology - Read more

CVC Capital offers €10.9B ($12.6B) takeover bid for Italian drugmaker Recordati, aiming to delist pharma company
Specialty pharma, rare disease, strategic, major transaction - Read more

Pulmatrix to reverse merge with Eos SENOLYTIX, focusing on anti-aging candidate PTC-2105 by mid-2026
Geropeptide, anti-aging, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Wave Life Sciences reports mixed Ph1 results for WVE-007 siRNA therapy targeting obesity
RNA interference, metabolic, siRNA, obesity, visceral fat reduction - Read more

IQVIA reports biopharma funding dropped 20% in 2025 despite surge in $2B+ deals
Small molecule, oncology, financial, strategic, major transaction - Read more

Robert Malone steps down from CDC's Advisory Committee on Immunization Practices amid mounting drama
Vaccine, infectious disease, strategic, operational - Read more

White House unlikely to name permanent CDC director by Wednesday deadline, agency remains without leader
Vaccines, infectious disease, regulatory, operational - Read more

Innate Pharma discontinues IPH6501 NK cell engager phase 1/2 trial in strategic pipeline refocus
NK cell engager, oncology, strategic, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here